Clinical Characteristics and Short-Term Prognosis of Children With Antibody-Mediated Autoimmune Encephalitis: A Single-Center Cohort Study

Qingyun Kang, Hongmei Liao, Liming Yang, Hongjun Fang, Wenjing Hu and Liwen Wu*

Department of Neurology, Hunan Children's Hospital, Changsha, China

Background: The incidence and prevalence of autoimmune encephalitis (AE) is gradually increasing in pediatric patients (between the ages of 3 months and 16 years). The aim of this retrospective observational study was to investigate the clinical characteristics and short-term prognosis of children with antibody-mediated AE at Hunan Children's Hospital.

Methods: Antibody analysis of blood and/or cerebrospinal fluid was performed in suspected AE patients admitted to the Department of Neurology, Hunan Children's Hospital from June 2014 to June 2021. Ultimately, 103 patients were diagnosed with antibody-mediated AE and were enrolled in this study. Clinical data and corresponding demographic, clinical characteristics, laboratory and imaging data, treatment, and prognosis data were collected and analyzed.

Results: In our study, 103 AE patients with antibody-positive were identified. The main subtype of AE in our cohort was anti-NMDAR encephalitis. Few patients have anti-CASPR2 encephalitis, anti-GABABR encephalitis, or anti-LGI1 encephalitis. In our AE patients, the most common clinical manifestations were behavioral symptoms, seizures, and involuntary movements, with seizures being the most common initial symptom. All patients underwent brain magnetic resonance imaging (MRI) and electroencephalography (EEG). Forty-five (43.7%) patients had abnormal MRI findings. And 96 (93.2%) patients had abnormal EEG results. All 103 patients were given first-line immunotherapy, 21 of which were also treated with the combination of the second-line immunotherapy. All surviving patients were followed up for at least 6 months. Seventy-seven patients recovered completely, 23 had sequelae of different degrees, and 3 died. Eight patients had one or more relapses during the follow-up period.

Conclusions: AE is a treatable disease that can occur in children of all ages. The mortality rate is low, as most patients have a good response to immune therapy. Compared with the older children, infants and young children (≤3 years old) with anti-NMDAR encephalitis have a higher incidence of fever and status epilepticus, more severe condition, higher PICU admission rate and worse prognosis. AE patients with high maximum mRS scores and PICU admissions may require second-line immunotherapy.

Keywords: autoimmune encephalitis, child, clinical characteristics, immunotherapy, prognosis
INTRODUCTION

Autoimmune encephalitis (AE) is a group of encephalitides caused by autoimmune mechanisms mediated by immune responses against the central nervous system (CNS) antigens. The disease spectrum of AE has been expanding since the first case of the anti-N-methyl-D-aspartic acid receptor (NMDAR) encephalitis was identified (1). The discovery and study of new anti-neural antibodies have made great strides in the study of various aspects of the etiology, pathogenesis, and treatment of AE (2–4).

AE affects the quality of patients’ life and imposes a serious economic burden on patients and society (5). However, most patients with autoimmune encephalitis are sensitive to immunotherapy. Previous studies have shown that early diagnosis and timely immunotherapy are key to improving the prognosis of AE (6, 7). Increased awareness of autoimmune encephalitis, early recognition, and timely completion of relevant antibody tests can improve the diagnosis rate of the disease. Although there are many studies on the clinical presentation, laboratory findings, immunotherapy, short-term prognosis, and other clinical data of AE (8–16), most studies have focused on adults. Studies on pediatric patients are still limited. More studies are needed for a better understanding of AE in children.

Here, we retrospectively analyzed the clinical characteristics, immunotherapy and short-term prognosis of children with AE admitted to Hunan Children’s Hospital, to provide a reference for the diagnosis and treatment of autoimmune encephalitis in children.

MATERIALS AND METHODS

Participants

The study was approved by the Ethics Committee of Hunan Children’s Hospital. In this retrospective cohort study, a total of 106 patients with positive neuron surface antibodies were identified by antibody testing. Three antibody-positive patients were excluded from further clinical analysis because of alternative diagnoses. Two patients with positive anti-CASPR2 antibodies detected in sera but not in CSF were eventually diagnosed with tuberous sclerosis and urea cycle disorder, respectively. One patient with positive anti-NMDAR antibodies detected in sera but not in CSF was eventually diagnosed with hereditary epilepsy. The other 103 patients who met the criteria for the AE criteria suggested by Graus et al. (8) were ultimately enrolled in our study: (1) subacute onset (rapid progression <3 months) with working memory deficits, altered state of consciousness, or behavioral symptoms; (2) presence of at least one of the following: new focal central nervous system (CNS) findings, seizures unexplained by previously known seizure disorders, CSF pleocytosis (white blood cell count >5 cells/mm³), or MRI features suggestive of encephalitis; and (3) reasonable exclusion of alternative causes. All subjects in the study were free of any disability prior to the onset of the disease.

Antibody Testing

The antibody panel included anti-NMDAR, anti-GABABR, anti-LGI1, anti-CASPR2, anti-AMPA1 receptor, and anti-AMPA2 receptor. The patients’ blood and cerebrospinal fluid samples were sent to Wuhan Kindstar Medical Laboratory and Guangzhou King Med Center for Clinical Laboratory. The laboratory analyzed the cerebrospinal fluid and serum of each patient using a highly specific and sensitive cell-based assay (CBA). The initial dilution titers of CSF and serum were 1:1 and 1:10, respectively.

Clinical Data Analysis

Clinical data of all subjects were retrospectively analyzed, including demographic characteristics, clinical symptoms, MRI findings, video EEG monitoring, cerebrospinal fluid findings, serum tumor markers, chest CT scan or x-ray, abdomen, and pelvic cavity CT scans or ultrasound, treatment and prognosis. All patients were followed up every 3 months in the first year after discharge, and every 6 months since the second year. All patients were followed up for at least 6 months. We used the modified Rankin scale (mRS) to measure neurological outcomes in all AE patients. MRS scores were determined by two experienced doctors at the onset, at the worst condition (recorded as the maximum mRS score), and at the last visit (recorded as the terminal mRS score). An mRS score of 0 at the last visit was considered a good outcome and ≥1 a poor outcome. AE patients with mRS scores of 0 at the last visit after treatments were assessed as recovering completely. AE relapse was defined as a recurrence or worsening of symptoms at least 2 months after improvement or stabilization of AE.

Statistical Analysis

SPSS 25.0 was used for statistical analysis. Measurements conforming to a normal distribution were presented as mean ± standard deviation. And two independent samples t-test was used for comparisons between groups. Statistical data were presented as percentages, and comparisons between groups were made using the χ² test or Fisher’s exact probability method. P < 0.05 was considered a statistically significant difference.

RESULTS

Demographic Features of AE Patients

In our study, detailed clinical data of 103 patients with antibody-positive autoimmune encephalitis were collected. Among these cases, 97 patients had anti-NMDAR encephalitis (1 patient was positive for both anti-NMDAR and anti-CASPR2 antibodies), 5 patients had anti-CASPR2 encephalitis (1 patient was positive for both anti-CASPR2 and anti-GABABR antibodies), 2 patients had anti-GABABR encephalitis, and 1 patient had anti-LGI1 encephalitis (Figure 1). In patients with anti-NMDAR encephalitis, antibodies were detected in both serum and CSF in 69 patients, in CSF only in 19 patients, and in serum only in 9 patients. In the group of patients with anti-CASPR2 encephalitis, antibodies were detected in both serum and CSF in 2 patients and serum only in the other 3 patients. In the group of patients...
with anti-GABABR encephalitis, antibodies were detected in both serum and CSF in 1 patient, and in serum only in the other patient. In the group of 1 patient with anti-LGI1 encephalitis, autoantibodies were detected in both serum and CSF (Table 1). Of the 103 patients included in the study, 47 were males and 56 were females. The youngest patient was only 3 months old, and the oldest patient was 16 years old. The median age of AE onset in the included patients was 87.2 months, and the peak frequencies of AE onset occurred at ages 3–6 and 6–9 years (Figure 2).

**Clinical Features of AE Patients**

Of the 103 patients with AE included in the study, 63 (61.2%) had an acute onset (≤2 weeks), 24 (23.3%) had a subacute onset (2 weeks to 1 month), and 16 (15.5%) had a chronic onset (>1 month). In our AE patients, the most common initial symptom was seizures, with behavioral symptoms being the most common clinical manifestation in the course of the disease. Other common clinical symptoms included disturbance of consciousness, memory deficit, speech disorders, involuntary movements, sleep disorder, headache, fever, and autonomic dysfunction. Some patients can also present with involuntary movements, sleep disorder, headache, fever, and autonomic dysfunction. Hyponatremia and faciobrachial dystonic seizures were observed in our patient with anti-LGI1 encephalitis. Clinical features of patients with different types of AE are summarized in Table 1.

**Auxiliary Examinations in AE Patients**

Cerebrospinal fluid (CSF) examination was performed in 102 of our 103 AE patients (prior to IVIG application). CSF pleocytosis (white blood cell count >5/mm³) was observed in 74 patients, and the maximum white blood cell count observed was 137/mm³. Elevated CSF protein levels (>500 mg/L) were observed in 9 patients, with the highest protein level being 820 mg/L. Brain MRI and EEG were performed and evaluated in all 103 patients. Brain MRI abnormalities were observed in 45 patients. Typical imaging findings of patients included in the study are shown in Figure 3. In the anti-NMDAR encephalitis group, abnormal brain MRI findings were observed in 43.3% of patients: abnormal fluid-attenuated inversion recovery (FLAIR) sequence signals associated with anti-NMDAR encephalitis were mainly found in the parietal, frontal, or temporal lobes. In the anti-CASPR2 encephalitis group, brain MRI abnormalities were observed in 2 patients (40%). All patients in the anti-GABABR and anti-LGI1 encephalitis groups had abnormal MRI findings in our study. EEG abnormalities were observed in 96 patients (93.2%). The most common abnormal EEG findings were focal or generalized non-specific slow waves (91.3%) and epileptiform discharges (such as sharp waves, spike waves, sharp slow wave complexes, or spike slow wave complexes) (41.7%). Twelve patients had seizures during video-EEG monitoring. A typical abnormal EEG showed diffusely slow waves and diffuse spike waves in Figure 4.

All 103 patients underwent chest X-rays or CT examinations. No tumors were found and only 5 patients were found to have pneumonia. We performed abdominal ultrasound or abdominal CT in 103 AE patients. Teratomas were observed in 2 patients with anti-NMDAR encephalitis, and the remaining patients had normal abdominal ultrasound or abdominal CT results.

In our study, 4 patients had anti-NMDAR encephalitis about 1–2 months following herpes simplex encephalitis (HSE). And HSE in these patients was confirmed by herpes simplex virus (HSV) PCR and HSV IgM antibody measurements of CSF. Multiple neuroautoantibodies were found to coexist in some patients. Six patients with anti-NMDAR and anti-MOG antibodies underwent MRI examinations of the spine and the optic nerve, of which 2 patients had abnormal spinal MRI and 4 patients had abnormal optic nerve MRI. Two patients had both anti-NMDAR antibodies and anti-GFAP antibodies. One patient had anti-NMDAR antibodies coexisting with anti-CASPR2 antibodies. And the other patient had anti-GABABR antibodies coexisting with anti-CASPR2 antibodies (Table 2).

**Treatment and Outcomes**

First-line immunotherapy (intravenous immunoglobulin, high-dose steroids, and plasma exchange) was used to care for pediatric patients with a diagnosis of AE. In our study, all 97 patients with anti-NMDAR encephalitis received the first-line immunotherapy. Two of these patients received IVIG only and 1 patient received a combination regimen of oral prednisone and IVIG. The remaining 94 patients were treated with a combination regimen of intravenous methylprednisolone (15–20 mg/kg/d for 5 days) and IVIG (400 mg/kg/d for 5 days). We used the modified Rankin scale (mRS) to assess the clinical efficacy on the 10–14th days of the treatment. Forty-two patients recovered well, 2 patients died due to autonomic dysfunction, and 53 patients recovered poorly. Of the 53 patients with poor recovery, 33 patients received a repeated regimen of intravenous methylprednisolone, with efficacy assessed weekly. A second round of intravenous methylprednisolone was determined based on clinical outcomes. Other 20 of 53 patients received the second-line immunotherapy (19 patients received rituximab and 1 patient received cyclophosphamide), and three of these patients were switched to the second-line immunotherapy after plasma exchange had failed (Table 3). Two patients with teratomas...
TABLE 1 | Demographic data and clinical features in AE patients.

| Patients | Autoimmune encephalitis (n = 103) | Anti-NMDAR (n = 97) | Anti-CASPR2 (n = 5) | Anti-LGI1 (n = 1) | Anti-GABABR (n = 2) |
|----------|----------------------------------|---------------------|---------------------|------------------|-------------------|
| Demographic data | | | | | |
| Age of onset range (month) | 3–192 | 3–192 | 25–118 | 157 | 88–118 |
| Sex (M:F) | 47:56 | 42:55 | 4:1 | 0:1 | 2:0 |
| Types of onsets, n (%) | | | | | |
| Acute (≤ 2 W) | 63 (61.2%) | 60 (61.9%) | 2 (40%) | 1 (100%) | 1 (50%) |
| Sub-acute | 24 (23.3%) | 21 (21.6%) | 3 (60%) | 0 | 1 (50%) |
| Chronic (≥ 1 M) | 16 (15.5%) | 16 (16.5%) | 0 | 0 | 0 |
| Positive antibody, n (%) | | | | | |
| CSF-serum pairs | 73 (70.9%) | 69 (71.1%) | 2 (40%) | 1 (100%) | 1 (50%) |
| Only CSF | 19 (18.4%) | 19 (19.6%) | – | – | – |
| Only sera | 11 (10.7%) | 9 (9.3%) | 3 (60%) | – | 1 (50%) |
| Initial symptoms, n (%) | | | | | |
| Seizures | 52 (50.5%) | 50 (51.5%) | 2 (40%) | 0 | 1 (50%) |
| behavioral symptoms | 25 (24.3%) | 22 (22.7%) | 2 (40%) | 1 (100%) | 1 (50%) |
| Others | 26 (25.2%) | 25 (25.8%) | 1 (20%) | 0 | 0 |
| Clinical symptoms, n (%) | | | | | |
| Seizures | 68 (66.1%) | 64 (65.9%) | 3 (60%) | 1 (100%) | 2 (100%) |
| Status epilepticus | 27 (26.2%) | 25 (25.8%) | 1 (20%) | 1 (100%) | 1 (50%) |
| behavioral symptoms | 86 (83.5%) | 81 (83.5%) | 5 (100%) | 1 (100%) | 1 (50%) |
| Disturbance of consciousness | 55 (53.4%) | 51 (52.6%) | 3 (60%) | 1 (100%) | 2 (100%) |
| Memory deficit | 45 (43.7%) | 36 (37.1%) | 2 (40%) | 1 (100%) | 2 (100%) |
| Speech disorders | 65 (63.1%) | 61 (62.9%) | 2 (40%) | 1 (100%) | 1 (50%) |
| Sleep disorder | 58 (56.3%) | 53 (54.6%) | 4 (80%) | 1 (100%) | 1 (50%) |
| Involuntary movements | 65 (63.1%) | 65 (67%) | 1 (20%) | 0 | 1 (50%) |
| Headache | 33 (32.0%) | 32 (32.98%) | 0 | 1 (100%) | 0 |
| Fever | 41 (39.8%) | 39 (40.2%) | 1 (20%) | 1 (100%) | 2 (100%) |
| Autonomic dysfunction | 28 (27.2%) | 25 (25.8%) | 3 (60%) | 0 | 1 (50%) |
| Faciobrachial dystonic seizures | 1 (0.97%) | 0 | 1 (100%) | 0 | 0 |
| Ataxia | 18 (17.5%) | 18 (18.6%) | 0 | 0 | 0 |
| Visual defect | 9 (8.7%) | 9 (9.3%) | 0 | 0 | 0 |
| Sensory disorder | 9 (8.7%) | 9 (9.3%) | 0 | 0 | 0 |

M, male; F, female; NMDAR, N-methyl D-aspartate receptor; CASPR2, contactin-associated protein-like; GABABR, γ-aminobutyric acid B receptor; LGI1, leucine-rich glioma inactivated 1; W, week; M, month.

underwent tumor resection. As shown in Table 4, among patients with anti-NMDAR encephalitis, there was a statistical significance (P < 0.05) between the groups of repeat first-line immunotherapy and second-line immunotherapy in terms of admission to the pediatric intensive care unit (PICU) and maximum mRS score.

Patients with anti-NMDAR encephalitis were followed up for at least 6 months after discharge, with a median follow-up period of 39.4 months (ranging from 6.0 to 89.8 months). The mRS scores of patients at the last follow-up were significantly lower than those of patients at the worst status (Figure 5A,B). At the last follow-up, 73 patients (75.3%) recovered completely, and 2 patients (2.1%) died. Sixteen patients (16.5%) had mild disability, with an mRS score of 1 in 6 patients and 2 in 10 patients. Six patients (6.2%) had a severe disability, with an mRS score of 3 in 5 patients and 4 in 1 patient. Residual symptoms in patients with incomplete recovery included seizures, cognitive dysfunction, and motor impairment. Eight patients (8.2%) experienced one or more relapses during the follow-up period. Statistically significant differences (P < 0.05) could be identified between the completely recovered group and the incompletely recovered group in terms of maximum mRS scores. Patients in the incompletely recovered group had a higher incidence of fever and status epilepticus, higher PICU admission rate, and a higher number of HSE diagnoses preceding the diagnosis of AE (Table 5).
All 5 patients with anti-CASPR2 encephalitis were treated with a combination of intravenous methylprednisolone and IVIG, 1 of which was also treated with rituximab (14 days after the treatment of IVIG) because of poor efficacy. One patient recovered completely after treatment and one patient died.

The only patient with anti-LGI1 encephalitis received a combination of intravenous methylprednisolone and IVIG and recovered after treatment.

**Young Children With Anti-NMDAR Encephalitis**

Among our 97 patients with anti-NMDAR encephalitis, there were 13 infants and young children (≤3 years old), 7 of whom were admitted to the PICU, 9 had brain MRI abnormalities, and 9 had recurrent fevers and eight had status epilepticus during the disease period. The mean maximum mRS score and the mean terminal mRS score were 4.62 and 1.54, respectively. Eight patients had sequelae of different degrees, which includes 4 patients with mRS score of 2 and 4 patients with mRS score of 3. Compared with older children, infants and young children (≤3 years old) had a higher incidence of fever and status epilepticus, a higher cranial MRI abnormality rate, a higher PICU admission rate, a higher mean maximum mRS score (Figures 3C,D), a higher mean terminal mRS score (Figures 3E,F), and a lower incidence of behavioral symptoms. All of these differences were statistically significant (P < 0.05) (Table 6).

**DISCUSSION**

With the increased awareness of AE and the ongoing discovery of relevant autoantibodies, an increasing number of encephalitis with unclear etiology have been diagnosed as AE. However, most studies reported on autoimmune encephalitis have focused on adult patients, and relatively few studies have been conducted on pediatric patients (9–11).

Among our 103 pediatric AE patients, 97 patients had anti-NMDAR encephalitis. The anti-NMDAR encephalitis was the most common type of AE in children, which is consistent
with the previous literature (11). Adult patients with anti-NMDAR encephalitis often have behavioral symptoms as the most common initial symptom. While seizures are often cited as the most common presenting symptom in children with anti-NMDA receptor encephalitis. In our study, the seizure was the initial symptom in 50 (51.5%) patients with anti-NMDAR encephalitis, which is similar to the previous report (12). In our patients, the most common clinical manifestations were behavioral symptoms, seizures, and involuntary movements. Other symptoms, such as disturbance of consciousness, speech disorders, status epilepticus, sleep disorder, and memory deficit, were as common as those reported in other literature. Infectious factors have been speculated to trigger a pro-inflammatory state. The immune system, including microglia and immune cells in the CNS, can be activated and then produce an autoimmune response against the CNS (13). This might explain the higher prevalence of fever and headache in anti-NMDAR encephalitis, which is consistent with our study and previous reports (14). In our study, the youngest age of onset in patients with anti-NMDAR encephalitis was 3 months, suggesting that the disease can occur at all stages of childhood. In the infant and young children (≤3 years old) group, the incidence of fever and status epilepticus during the disease was higher, the disease was more severe, and the average maximum mRS score was higher. The prognosis was worse in younger children than in older children. We speculate that this may be related to the high incidence of fever and status epilepticus in younger children, the occurrence of which may exacerbate brain damage. Such differences have not been reported in other reports, which need to be verified in studies with larger samples.

With the continuous expansion of the anti-neural antibody spectrum and the widespread application of antibody testing, more and more patients with AE have been diagnosed. Recently, an increasing number of patients with autoimmune encephalitis have been found to have overlapping autoantibodies. The overlap of antibodies, especially pathogenic antibodies, can lead to an overlap of clinical phenotypes. In our study, 6 patients with concomitant anti-NMDAR antibodies and anti-MOG antibodies presented with clinical symptoms of both acute demyelinating diseases and anti-NMDAR encephalitis. The coexistence of anti-NMDAR antibodies and anti-MOG antibodies has been reported in previous studies (17, 18). In addition, there is an overlap between anti-NMDAR antibodies and other neurological autoantibodies. The pathological immune mechanisms underlying the phenomenon of multiple antibody overlap are unknown. It is speculated that simultaneous or successive exposure to different autoantigens under the condition of abnormal immune activation may initiate a series of autoimmune reactions that produce different autoantibodies and induce different autoimmune diseases. The presence of multiple

![FIGURE 4](image-url) | Electroencephalogram (EEG) of a 6-years old male patient with anti-NMDA receptor encephalitis. The delta rhythm (1.2–3 Hz, 80–250 UV) was used as the main background, with a small amount of θ rhythms (4–5 Hz, 40–100 UV) and slightly more low amplitude beta activity (A). During video-EEG monitoring, the child had a seizure with oblique eyes, unconsciousness and smack mouth. The synchronous EEG was the mid-amplitude spike rhythm starting from the left occipital and posterior temporal regions, and the discharge stopped briefly after intravenous injection of midazolam (B–D).
TABLE 2 | Auxiliary examinations of AE patients.

| Patients | Autoimmune encephalitis (n = 103) | Anti-NMDAR (n = 97) | Anti-CASPR2 (n = 5) | Anti-LGI1 (n = 1) | Anti-GABABR (n = 2) |
|----------|-----------------------------------|---------------------|---------------------|-------------------|---------------------|
| CSF analysis, n (%) |  |  |  |  |  |
| Increased level of protein | 9 (8.7%) | 6 (6.2%) | 1 (20%) | 0 | 0 |
| CSF pleocytosis (>5/mm³) | 74 (71.8%) | 69 (71.1%) | 4 (80%) | 1 (100%) | 2 (100%) |
| Patients with abnormal brain MRI findings |  |  |  |  |  |
| Total with abnormal findings | 45 (43.7%) | 42 (43.3%) | 2 (40%) | 1 (100%) | 2 (100%) |
| Parietal lobe | 29 (28.2%) | 28 (28.9%) | 1 (20%) | 0 | 1 (50%) |
| Temporal lobe | 23 (22.3%) | 21 (21.6%) | 1 (20%) | 1 (100%) | 1 (50%) |
| Frontal lobe | 26 (25.2%) | 25 (25.8%) | 1 (20%) | 0 | 1 (50%) |
| Occipital lobe | 16 (15.5%) | 15 (15.5%) | 1 (20%) | 0 | 1 (50%) |
| Thalamus | 17 (16.5%) | 15 (15.5%) | 2 (40%) | 0 | 2 (100%) |
| Insular lobe | 10 (9.7%) | 9 (9.3%) | 1 (20%) | 0 | 1 (50%) |
| Basal ganglia | 8 (7.8%) | 7 (7.2%) | 0 | 0 | 1 (50%) |
| Cerebellum | 6 (5.8%) | 6 (6.2%) | 0 | 0 | 0 |
| Brain stem | 2 (1.9%) | 2 (2.1%) | 0 | 0 | 0 |
| Others | 6 (5.8%) | 5 (5.2%) | 1 (20%) | 0 | 1 (50%) |
| Patients with abnormal EEG |  |  |  |  |  |
| Total with abnormal findings | 96 (93.2%) | 90 (92.8%) | 5 (100%) | 1 (100%) | 2 (100%) |
| Slow waves | 94 (88.3%) | 88 (90.7%) | 5 (100%) | 1 (100%) | 2 (100%) |
| Epileptic discharges | 43 (41.7%) | 39 (40.2%) | 2 (40%) | 1 (100%) | 2 (100%) |
| Others |  |  |  |  |  |
| Complicated with tumors | 2 (1.9%) | 2 (2.1%) | 0 | 0 | 1 (50%) |
| MOG-positive (serum) | 6 (5.8%) | 6 (6.2%) | 0 | 0 | 0 |
| Secondary to HSV encephalitis | 4 (3.9%) | 4 (4.1%) | 0 | 0 | 0 |

TABLE 3 | Summary of treatment and outcome results of AE patients.

| Patients | Autoimmune encephalitis (n = 103) | Anti-NMDAR (n = 97) | Anti-CASPR2 (n = 5) | Anti-LGI1 (n = 1) | Anti-GABABR (n = 2) |
|----------|-----------------------------------|---------------------|---------------------|-------------------|---------------------|
| Treatment, n (%) |  |  |  |  |  |
| Only Steroids | 0 | 0 | 0 | 0 | 0 |
| Only IVIG | 2 (1.9%) | 2 (2.1%) | 0 | 0 | 0 |
| Steroids + IVIG | 101 (98.1%) | 95 (97.9%) | 4 (80%) | 1 (100%) | 1 (50%) |
| Steroids + IVIG + PE | 3 (2.9%) | 3 (3.1%) | 0 | 0 | 0 |
| Second-line treatment | 21 (20.4%) | 20 (20.6%) | 1 (20%) | 0 | 1 (50%) |
| Cases requiring PICU admission | 28 (27.2%) | 26 (26.8%) | 2 (40%) | 0 | 2 (100%) |
| Prognosis, n (%) |  |  |  |  |  |
| Complete recovery | 77 (74.8%) | 73 (75.6%) | 4 (80%) | 1 (100%) | 1 (50%) |
| Epilepsy | 7 (6.8%) | 7 (7.2%) | 0 | 0 | 0 |
| Cognitive dysfunction | 16 (15.5%) | 15 (15.5%) | 1 (20%) | 0 | 0 |
| Movement disorder | 5 (4.9%) | 5 (5.2%) | 0 | 0 | 0 |
| Relapse | 8 (7.8%) | 8 (8.2%) | 0 | 0 | 0 |
| Mortality | 3 (2.9%) | 2 (2.1%) | 0 | 0 | 1 (50%) |
TABLE 4  | The comparison of clinical data between groups of repeated first-line immunotherapy and second-line immunotherapy in patients with anti-NMDAR encephalitis, case (%).

| Clinical information | Total | Repeated first-line immunotherapy \((n = 33)\) | Second-line immunotherapy \((n = 20)\) | \(t/\chi^2\) | \(P\) |
|----------------------|-------|---------------------------------------------|---------------------------------------------|----------------|-------|
| Sex, male            |       | 20 (37.74%)                               | 10 (50.00%)                                | 2.056          | 0.152 |
| Age (month)          | 77.53 ± 46.8 | 76.58 ± 45.3                        | 79.1 ± 50.34                               | -0.189         | 0.851 |
| Average maximum mRS score | 4.11 ± 0.67 | 3.88 ± 0.6                               | 4.5 ± 0.61                                 | -3.638         | 0.001 |
| Average terminal mRS score | 0.7 ± 1.31  | 0.58 ± 0.97\(^a\)                    | 0.9 ± 1.74\(^a\)                           | -0.763         | 0.452 |
| Pleocytosis          | 40 (75.47%) | 23 (69.70%)                                | 17 (85.00%)                                | /              | 0.325 |
| Cranial MRI abnormalities | 27 (50.94%) | 16 (48.48%)                                | 11 (55.00%)                                | 0.212          | 0.646 |
| EEG abnormalities    | 45 (84.91%) | 26 (78.79%)                                | 19 (95.00%)                                | /              | 0.234 |
| Admission to PICU    | 18 (33.96%) | 5 (15.15%)                                 | 13 (65.00%)                                | 13.797        | <0.001 |
| Fever                | 23 (43.40%) | 11 (33.33%)                                | 12 (60.00%)                                | 3.605          | 0.058 |
| Seizures             | 34 (64.15%) | 21 (63.64%)                                | 13 (65.00%)                                | 0.763          | 0.452 |
| Status epilepticus   | 17 (32.08%) | 12 (36.36%)                                | 5 (25.00%)                                 | 0.738          | 0.39  |
| behavior disturbance | 46 (86.79%) | 28 (84.55%)                                | 18 (80.00%)                                | /              | 0.697 |
| Disturbance of consciousness | 35 (66.04%) | 20 (60.61%)                                | 15 (75.00%)                                | 1.15           | 0.283 |
| Involuntary movements | 42 (79.25%) | 27 (81.82%)                                | 15 (75.00%)                                | /              | 0.728 |
| Positive for multiple antibodies | 1 (1.89%) | 1 (3.03%)                                    | 0 (0.00%)                                   | /              | >0.999 |
| Prior diagnosis of HSE | 2 (3.77%) | 1 (3.03%)                                    | 1 (5.00%)                                   | /              | >0.999 |
| with teratomas       | 1 (1.89%) | 0 (0.00%)                                    | 1 (5.00%)                                   | /              | 0.377 |

\(^a\)Compared with maximum mRS score, \(P < 0.05\).

FIGURE 5 | Comparison of the modified Rankin Scale (mRS) scores. The maximum mRS scores (A) and terminal mRS scores (B) in the anti-NMDAR encephalitis group. The maximum mRS scores in the ≤3-year-old group (C) and >3-year-old group (D). Terminal mRS scores in the ≤3-year-old group (E) and >3-year-old group (F). **\(P < 0.01\); ***\(P < 0.001\); ****\(P < 0.0001\).

neurological autoantibodies in the same patient has caused great confusion in clinical diagnosis and treatment. Whether the coexistence of multiple neuroimmune diseases can be diagnosed based on the presence of multiple neurological autoantibodies and whether each antibody can be used as a basis for disease monitoring and efficacy determination remains to be explored and resolved.

In our study, 4 patients had HSV infection in the CNS, subsequently, these patients had NMDAR encephalitis about 1–2 months following HSE. HSE and other possible viral encephalitides can trigger antibodies against the NMDAR and other neuronal cell-surface proteins (19). The molecular mimicry or disruption of immune tolerance may be the causation (20). More and more studies have reported that some patients with viral encephalitis, especially those with herpes simplex encephalitis and Japanese encephalitis, have a typical course of “bimodal encephalitis,” with the first phase being viral encephalitis and the second phase being the propagation of auto-antibodies wrongly targeting otherwise healthy cells. When patients recovering from viral encephalitis show symptoms such as behavioral symptoms, memory deficit, involuntary movements, and autonomic dysfunction, AE should be considered as a possibility and treated as early as possible.

In a study reported by Zhang et al. 89 pediatric patients had anti-NMDAR encephalitis (11). Among these patients, 29 patients (32.6%) had cranial MRI abnormalities, which were most commonly located in the temporal lobe (23.6%). This result was similar to our study (total abnormality in 43.3%, temporal...
TABLE 5 | Comparison of clinical data of patients with anti-NMDAR encephalitis between the completely-recovered and incompletely-recovered groups, case (%).

| Clinical information                  | Total          | Incompletely-recovered (n = 24) | Completely-recovered (n = 73) | t/χ²       | P     |
|---------------------------------------|----------------|---------------------------------|------------------------------|-----------|-------|
| Sex, male                             | 42 (43.30%)    | 11 (45.83%)                     | 31 (42.47%)                  | 0.083     | 0.773 |
| Age (month)                           | 85.94 ± 45.5   | 73.92 ± 53.15                  | 89.89 ± 42.36                | −1.502    | 0.137 |
| Average maximum mRS score             | 3.67 ± 1.01    | 4.29 ± 0.75                    | 3.47 ± 1                     | 3.708     | <0.001|
| Pleocytosis                           | 69 (71.13%)    | 18 (75.00%)                    | 51 (69.86%)                  | 0.232     | 0.63  |
| Cranial MRI abnormalities             | 42 (43.30%)    | 13 (54.17%)                    | 29 (39.73%)                  | 1.534     | 0.215 |
| EEG abnormalities                     | 90 (92.78%)    | 24 (100.00%)                   | 66 (90.41%)                  |           | 0.188 |
| Admission to PICU                     | 26 (26.80%)    | 12 (50.00%)                    | 14 (19.18%)                  | 8.746     | 0.003 |
| Fever                                 | 39 (40.21%)    | 14 (58.33%)                    | 25 (34.25%)                  | 4.359     | 0.037 |
| Seizures                              | 64 (65.98%)    | 18 (75.00%)                    | 46 (63.01%)                  | 1.156     | 0.282 |
| Status epilepticus                    | 25 (25.77%)    | 11 (45.83%)                    | 14 (19.18%)                  | 6.708     | 0.01  |
| behavioral symptoms                   | 81 (83.51%)    | 20 (83.33%)                    | 61 (83.66%)                  |           | >0.999|
| Disturbance of consciousness          | 51 (52.58%)    | 15 (62.50%)                    | 36 (49.32%)                  | 1.259     | 0.262 |
| Involuntary movements                 | 65 (67.01%)    | 18 (75.00%)                    | 47 (63.88%)                  | 0.921     | 0.337 |
| Positive for multiple antibodies      | 8 (8.25%)      | 1 (4.17%)                      | 7 (9.59%)                    |           | 0.675 |
| Secondary to herpes simplex encephalitis with teratomas | 4 (4.12%) | 3 (12.50%) | 1 (1.37%) | / | 0.046 |
| /Fisher exact test without statistic. |               |                                |                             |           |       |

TABLE 6 | Comparison of clinical data of patients with anti-NMDAR encephalitis, between the >3-year-old group and the ≤3-year-old group, case (%).

| Clinical information                  | Total          | >3-year-old group (n = 84) | ≤3-year-old group (n = 13) | t/χ²       | P     |
|---------------------------------------|----------------|-----------------------------|----------------------------|-----------|-------|
| Sex, male                             | 42 (43.30%)    | 36 (42.66%)                 | 6 (46.15%)                 | 0.05      | 0.823 |
| Average maximum mRS score             | 3.67 ± 1.01    | 3.52 ± 0.98                 | 4.62 ± 0.65                | −3.894    | <0.001|
| Average terminal mRS score            | 0.59 ± 1.23    | 0.44 ± 1.15                 | 1.54 ± 1.33                | −3.126    | 0.002 |
| Pleocytosis                           | 69 (71.13%)    | 61 (72.62%)                 | 8 (61.54%)                 |           | 0.512 |
| Cranial MRI abnormalities             | 42 (43.30%)    | 33 (39.29%)                 | 9 (69.23%)                 | 4.112     | 0.043 |
| EEG abnormalities                     | 90 (92.78%)    | 77 (91.67%)                 | 13 (100.00%)               |           | 0.589 |
| Admission to PICU                     | 26 (26.80%)    | 19 (22.62%)                 | 13 (100.00%)               |           | 0.038 |
| Fever                                 | 39 (40.21%)    | 30 (35.71%)                 | 9 (69.23%)                 | 5.26      | 0.022 |
| Seizures                              | 64 (65.98%)    | 52 (61.90%)                 | 12 (92.31%)                |           | 0.055 |
| Status epilepticus                    | 25 (25.77%)    | 17 (20.24%)                 | 13 (100.00%)               |           | 0.004 |
| behavioral symptoms                   | 81 (83.51%)    | 73 (86.90%)                 | 8 (61.54%)                 |           | 0.037 |
| Disturbance of consciousness          | 51 (52.58%)    | 42 (50.00%)                 | 9 (69.23%)                 | 1.67      | 0.196 |
| Involuntary movements                 | 65 (67.01%)    | 54 (64.29%)                 | 11 (84.62%)                |           | 0.209 |
| Positive for multiple antibodies      | 9 (9.28%)      | 8 (9.52%)                   | 1 (7.69%)                  |           | >0.999|
| Secondary to HSE                      | 4 (4.12%)      | 3 (3.57%)                   | 1 (7.69%)                  |           | 0.443 |

/Fisher exact test without statistic; aCompared with maximum mRS score, P < 0.05.

lobe abnormality in 21.6%). This result might explain the high incidence of epileptic seizures in patients with AE, as medial temporal structures are key to the neural circuitry and play an important role in seizure propagation. In addition to frequent temporal lobe involvement, the frontal and parietal lobes were often involved in our cohort, with higher rates of frontal and parietal abnormalities than in previous studies (14). In our study, the rate of MRI abnormalities was higher in younger...
because we used mRS score in our cohort was lower than those in other study cohorts, discharge indicated clinical or subclinical epileptic activity (whereas other studies considered mRS score ≤ 10). Previous studies reported by Titulaer et al. In Western countries, second-line therapy is applied to a much larger proportion of patients, as it is commonly used in those who have failed the first-line therapy (12). However, in China, second-line immunotherapy is only used in a relatively small proportion of AE patients, usually in patients with severe or relapsing diseases. Our research suggests that patients with a higher maximum mRS score and PICU admission may not respond well to the first-line immunotherapy, and therefore may require the second-line immunotherapy. However, in the treatment of children with anti-NMDAR encephalitis, when aggressive immunotherapy is administered without significant improvement in clinical symptoms, whether to wait for natural improvement or to pursue more aggressive immunotherapy needs to be further validated in prospective large sample studies.

In our cohort, a high percentage of patients achieved a good prognosis, with 77 patients (74.8%) recovering completely. The rate of complete recovery was comparable to previous pediatric cohort studies (84.3%) (11). However, the rate of good prognosis in our cohort was lower than those in other study cohorts, because we used mRS score = 0 as a good prognosis criterion, whereas other studies considered mRS score ≤ 2 as a good prognosis (25). Data on morbidity and mortality in pediatric AE patients are less reported. Previous studies reported by Titulaer et al. and Zhang et al. showed low mortality rates in children with pediatric AE (2.7 and 1.1%, respectively), which were similar to our findings (mortality rate of 2.9%) (21, 26). The mortality rate of AE in pediatric patients is lower than that in adult patients. This may be due to the lower rate of tumors in children than in adults, children are less prone to autonomic dysfunction and hypoventilation. Of course, further statistical studies with more samples are needed to confirm these conjectures. Eight patients (7.8%) relapsed and improved after the second-line treatment, which was broadly consistent with the results of previous studies (11, 12).

In previous studies, patients who were treated early and did not require PICU admission during the disease had a good prognosis, whereas patients with a young age of onset, disturbance of consciousness, memory deficit, and status epilepticus had a poor prognosis (11, 12, 27, 28). In our study, admission to PICU and status epilepticus were high-risk factors for poor prognosis, which were consistent with previous findings. In contrast to previous studies, our study also found that recurrent fevers and secondary herpes simplex encephalitis were also high-risk factors for poor prognosis in patients with anti-NMDAR encephalitis.

Among all the AE patients in our study, only 2 patients with anti-NMDAR encephalitis had ovarian teratomas, suggesting that children, especially young children, rarely have tumors, which is consistent with the results reported in previous studies (11, 12). In addition, the proportion of our AE patients with fever, vomit, and headache was high, suggesting that infectious factors may be the major triggers for the development of AE in children.

Limitations of our study include its retrospective methodology, and the retrospective nature of the study, which may allow for selection bias. The mRS in real-time at the initial evaluations was documented, but there are retrospective data at the follow-up evaluations, which may result in inadequate accuracy during reporting. The inferences of this study are limited. In addition, the mRS score values for our good prognosis differed from previous studies, which could make the data less generalizable and/or ineligible for inclusion in a meta-analysis. However, this study is one of the largest series of pediatric autoimmune encephalitis patients in China, which has certain representativeness and provides a basis for future studies. In the future, prospective, large-scale, randomized, controlled trials can be conducted to further explore prognostic factors and validate the findings.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article.supplementary material, further inquiries can be directed to the corresponding author/s.

ETHICS STATEMENT

Written informed consent was obtained from the minor(s)’ legal guardian/next of kin for the publication of any potentially identifiable images or data included in this article.

AUTHOR CONTRIBUTIONS

QK conducted the literature review and drafted the manuscript. HL, LY, HF, and WH made substantial contributions to the conception and interpretation of data. LW was responsible for revising the manuscript critically and has given final approval for the version to be published. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by grants from the National Natural Science Foundation of China (No. 2021JJ30393).
REFERENCES

1. Dalmau J, Bataller L. Clinical and immunological diversity of limbic encephalitis: a model for paraneoplastic neurologic disorders. *Hematol Oncol Clin North Am.* (2006) 20:1319–35. doi: 10.1016/j.hoc.2006.09.011

2. Bien CG. Management of autoimmune encephalitis. *Curr Opin Neurol.* (2011) 34:166–71. doi: 10.1097/WCO.0b013e3283400999

3. Hermetter C, Fazekas F, Hoehmeister S. Systematic review: syndromes, early diagnosis, and treatment in autoimmune encephalitis. *Front Neurol.* (2018) 9:706. doi: 10.3389/fneur.2018.00706

4. Wagon I, Helie P, Bardou I, Regnault C, Lesec L, Leprince J, et al. Autoimmune encephalitis mediated by B-cell response against N-methyl-D-aspartate receptor. *Brain.* (2020) 143:2957–72. doi: 10.1093/brain/awa250

5. Cohen J, Sotoca J, Gandhi S, Yeshokumar AK, Gordon-Lipkin E, Geocadin RG, et al. Autoimmune encephalitis: a costly condition. *Neurology.* (2019) 92:e964–72. doi: 10.1212/WNL.0000000000096990

6. Alexopoulos H, Dalakas MC. The immunobiology of autoimmune encephalitides. *J Autoimmun.* (2019) 104:102339. doi: 10.1016/j.jaut.2019.102339

7. Pradhan S, Das A, Mani VE. Immunotherapy in autoimmune encephalitis: A need for “presumptive” diagnosis and treatment. *Neurology India.* (2018) 66:1584. doi: 10.4103/0028-3886.246277

8. Graus F, Titulaer MJ, Balu R, Benseler S, Cellucci T, et al. A clinical approach to diagnosis of autoimmune encephalitis. *Lancet Neurol.* (2016) 15:391–404. doi: 10.1016/S1474-4422(15)00409-9

9. de Bruijn M, Aarsen FK, van Oosterhout MP, van der Knoop MM, Catsman-Berrevoets CE, Schreurs MWJ, et al. Long-term neuropsychological outcome following pediatric anti-NMDAR encephalitis. *Neurology.* (2018) 90:e1997–2005. doi: 10.1212/WNL.000000000005605

10. Granata T, Matricardi S, Ragona F, Ferri E, Zibordi F, Andreotta F, et al. Pediatric NMDAR encephalitis: a single center observation study with a closer look at movement disorders. *Eur J Paed Neurol.* (2018) 22:301–7. doi: 10.1016/j.ejpn.2018.01.012

11. Zhang J, Ji T, Chen Q, Jiang Y, Cheng H, Zheng P, et al. Pediatric autoimmune encephalitis: case series from two chinese tertiary pediatric neurology centers. *Front Neurol.* (2019) 10:906. doi: 10.3389/fneur.2019.00906

12. Titulaer MJ, McCracken L, Gabilondo I, Armandgue T, Glaser C, Izuka T, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. *Lancet Neurol.* (2013) 12:157–65. doi: 10.1016/S1474-4422(12)70310-1

13. Platt MP, Agalliu D, Cuthforth T. Hello from the other side: how auto antibodies circumvent the blood-brain barrier in autoimmune encephalitis. *Front Immunol.* (2017) 8:442. doi: 10.3389/fimmu.2017.00442

14. Shan W, Yang H, Wang Q. Neuronal surface antibody-medicated autoimmune encephalitis (Limbic Encephalitis) in China: a multiple-center, retrospective study. *Front Immunol.* (2021) 12:621599. doi: 10.3389/fimmu.2021.621599

15. Swayne A, Warren N, Prain K, Gillis D, O’Gorman C, Tsang BK, et al. An australian state-based cohort study of autoimmune encephalitis cases detailing clinical presentation, investigation results, and response to therapy. *Front Neurol.* (2021) 12:607773. doi: 10.3389/fneur.2021.607773

16. Guan H-Z, Ren H-T, Yang X-Z, Lu Q, Peng B, Zhu Y-C, et al. Limbic encephalitis associated with anti-γ-aminobutyric acid B receptor antibodies: a case series from China. *Chin Med J.* (2015) 128:3023–8. doi: 10.4103/0366-6999.168989

17. Hou C, Wu W, Tian Y, Zhang Y, Zhu H, Zeng Y, et al. Clinical analysis of anti-NMDAR encephalitis combined with MOG antibody in children. *Mult Scler Relat Disord.* (2020) 42:102018. doi: 10.1016/j.msard.2020.102018

18. Perez CA, Aggey P, Gogia B, Harrison R, Samudralwar R. Overlapping autoimmune syndrome: a case of concomitant anti-NMDA encephalitis and myelin oligodendrocyte glycoprotein (MOG) antibody disease. *J Neuroimmunol.* (2020) 339:577124. doi: 10.1016/j.jneuroim.2019.577124

19. Dalmau J, Graus F. Antibody-mediated encephalitis. *N Engl J Med.* (2018) 378:840–51. doi: 10.1056/NEJMra1708712

20. Wesselingh R, Broadley J, Kyndt C, Buzzard K, O’Brien T, Monif M. 005 Electroclinical Characteristics of Autoimmune Encephalitis as Outcome Biomarkers. BMJ Publishing Group Ltd (2019).

21. Deng S, Qiu K, Liu H, Wu X, Lei Q, Lu W. Clinical characteristics and short-term prognosis of autoimmune encephalitis: a single-center cohort study in Changsha, China. *Front Neurol.* (2019) 10:539. doi: 10.3389/fneur.2019.00539

22. Mueller SH, Färber A, Prüss H, Melzer N, Golombbeck KS, Kümpfel T, et al. Genetic predisposition in anti-LGI1 and anti-NMDA receptor encephalitis. *Ann Neurol.* (2018) 83:863–9. doi: 10.1002/ana.25216

23. Gu Y, Zhong M, He L, Li W, Huang Y, Liu J, et al. Epidemiology of antibody-positive autoimmune encephalitis in southwest china: a multicenter study. *Front Immunol.* (2019) 10:2611. doi: 10.3389/fimmu.2019.02611

24. Qiu X, Zhang H, Li D, Wang J, Jiang Z, Zhou Y, et al. Analysis of clinical characteristics and poor prognostic predictors in patients with an initial diagnosis of autoimmune encephalitis. *Front Immunol.* (2019) 10:1286. doi: 10.3389/fimmu.2019.01286

25. Xu X, Lu Q, Huang Y, Fan S, Zhou L, Yuan J, et al. Anti-NMDAR encephalitis: a single-center, longitudinal study in China. *Neural Neuroimmunol.* (2020) 7:e633. doi: 10.1212/NXI.0000000000006633

26. Hayden Z, Böné B, Orsi G, Szots M, Nagy F, Csépány T, et al. Clinical characteristics and outcome of neuronal surface antibody-mediated autoimmune encephalitis patients in a national cohort. *Front Neurol.* (2021) 12:611397. doi: 10.3389/fneur.2021.611397

27. Gresa-Arribas N, Titulaer MJ, Torrents A, Aguilar E, McCracken L, Leypoldt F, et al. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. *Lancet Neurol.* (2014) 13:167–77. doi: 10.1016/S1474-4422(13)70282-5

28. Lim JA, Lee ST, Jung KH, Kim S, Shin JW, Moon J, et al. Anti-N-methyl-D-aspartate receptor encephalitis in Korea: clinical features, treatment, and outcome. *J Clin Neurol.* (2014) 10:157–61. doi: 10.3988/jcn.2014.10.2.157

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Kang, Liao, Yang, Fang, Hu and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided that the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.